Axsome Therapeutics Inc
AXSM182.550USD
+1.710+0.95%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
9.18BCap. mercado
PérdidaP/E TTM
Más Datos de Axsome Therapeutics Inc Compañía
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Información de Axsome Therapeutics Inc
Símbolo de cotizaciónAXSM
Nombre de la empresaAxsome Therapeutics Inc
Fecha de salida a bolsaNov 19, 2015
Director ejecutivoTabuteau (Herriot)
Número de empleados683
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 19
DirecciónOne World Trade Center, 29Th Floor
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10007
Teléfono12123323241
Sitio Webhttps://www.axsome.com/
Símbolo de cotizaciónAXSM
Fecha de salida a bolsaNov 19, 2015
Director ejecutivoTabuteau (Herriot)
Ejecutivos de Axsome Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-13464.00%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
--
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-5783.00%
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
Por negocioUSD
Nombre
Ganancia
Proporción
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
169.18M
98.94%
Outside of the United States
1.82M
1.06%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Auvelitv
136.10M
79.60%
Sunosi
31.61M
18.49%
Symbravo
2.07M
1.21%
Sunosi royality revenue
1.21M
0.71%
Estadísticas de accionistas
Actualizado: dom., 11 de ene
Actualizado: dom., 11 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Otro
66.16%
Accionistas
Accionistas
Proporción
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.24%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Otro
66.16%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.67%
Investment Advisor/Hedge Fund
22.02%
Corporation
14.57%
Hedge Fund
11.48%
Research Firm
2.23%
Private Equity
1.35%
Individual Investor
1.13%
Pension Fund
1.09%
Sovereign Wealth Fund
0.93%
Otro
8.52%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
669
38.98M
77.33%
-4.18M
2025Q3
657
38.45M
87.16%
-264.98K
2025Q2
636
38.74M
85.21%
+673.17K
2025Q1
604
38.08M
85.89%
-4.20M
2024Q4
561
37.78M
89.40%
-1.53M
2024Q3
529
39.25M
94.83%
-2.09M
2024Q2
515
41.51M
92.29%
+1.90M
2024Q1
502
39.61M
93.44%
-4.74M
2023Q4
476
39.34M
91.45%
+441.54K
2023Q3
467
38.94M
87.84%
+1.52M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Antecip Capital, L.L.C.
7.34M
14.57%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
4.17M
8.28%
+235.15K
+5.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.10M
6.16%
-38.55K
-1.23%
Sep 30, 2025
Wellington Management Company, LLP
1.33M
2.65%
+609.52K
+84.07%
Sep 30, 2025
RTW Investments L.P.
1.12M
2.22%
-398.02K
-26.24%
Sep 30, 2025
Nomura Investment Management Business Trust
1.08M
2.15%
-53.21K
-4.68%
Sep 30, 2025
Geode Capital Management, L.L.C.
997.70K
1.98%
+8.25K
+0.83%
Sep 30, 2025
T. Rowe Price Associates, Inc.
994.50K
1.97%
+418.57K
+72.68%
Sep 30, 2025
Invesco Advisers, Inc.
949.36K
1.88%
+420.83K
+79.62%
Sep 30, 2025
State Street Investment Management (US)
942.96K
1.87%
-15.54K
-1.62%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.69%
ALPS Medical Breakthroughs ETF
2.85%
State Street SPDR S&P Pharmaceuticals ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.73%
iShares U.S. Pharmaceuticals ETF
2.09%
Virtus LifeSci Biotech Products ETF
2.03%
ProShares Ultra Nasdaq Biotechnology
0.92%
iShares Health Innovation Active ETF
0.89%
JPMorgan Healthcare Leaders ETF
0.8%
VanEck Pharmaceutical ETF
0.75%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.69%
ALPS Medical Breakthroughs ETF
Proporción2.85%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.73%
iShares U.S. Pharmaceuticals ETF
Proporción2.09%
Virtus LifeSci Biotech Products ETF
Proporción2.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.92%
iShares Health Innovation Active ETF
Proporción0.89%
JPMorgan Healthcare Leaders ETF
Proporción0.8%
VanEck Pharmaceutical ETF
Proporción0.75%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
